The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
TCT 2021 | Cord blood-derived NK cells with high-dose chemotherapy & ASCT for B-NHL
Yago Nieto, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the findings of a novel cellular ex vivo-expanded cord blood-derived NK cellular therapy in patients with B-cell non-Hodgkin lymphoma (B-NHL) receiving high-dose chemotherapy and autologous stem cell transplantation (ASCT). The use of expanded and purified cord blood-derived NK cells, combined with high-dose chemotherapy and ASCT is safe and demonstrates early promising results in patients with B-NHL. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.
